|
|
|
Corporate Profile: Ceptaris Therapeutics
| Summary: |
Ceptaris Therapeutics is focused on the development of a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides.
|
| Address (HQ): |
101 Lindenwood Drive
Suite 400
Malvern, PA 19355 |
| Phone
#'s (HQ): |
| Main |
(610) 975-9290 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| Fax
#'s (HQ): |
| Main |
(610) 975-9012 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| email: |
| Main |
not known |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| Internet
job postings: |
| not known |
| Number
of employees: |
| not known |
| Issued United States patents: |
| Issued U.S. patents: 1976-present: patent
link. |
| Filed United States patent applications: |
| Filed U.S. patent applications: 2001-present: patent
link. |
| Publications on PubMed: |
| Scientific publications mentioning company on PubMed: publications
link. |
|
|
|
